BCLI
HOLD / NEUTRALMeanRevComposite
56.00
Technical
84.50
Fundamental
46.50
Rank
—
Price
1.07
Hurst
0.10
As of
Sep 4, 2026
Daily
Brainstorm Cell Therapeutics Inc.
HealthcareBiotechnologyBrainstorm Cell Therapeutics is a biotechnology company developing cellular therapies derived from patients' own bone marrow stem cells to treat neurodegenerative conditions. The company's NurOwn platform uses cultured stem cells engineered to produce high levels of protective proteins that reduce inflammation and neurodegeneration while supporting nerve cell survival. The therapy is currently in clinical testing for amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's disease, and other degenerative neurological disorders.
Market cap
$10.2M
P/E (trailing)
—
P/E (forward)
-0.90
PEG ratio
—
Dividend yield
—
Beta
0.26
52w range
0.46 – 1.69
Return on equity
—
Profit margin
0.00%
Revenue growth
—
Earnings growth
—
Price history
1Y: 0.98 (+46.3%) · range 0.48–1.44
Cycle position
47/ 100 cycle scoreMID-BULL
ENTRYAPPROACHMID-BULLNEAR-TOPEXIT
entry readiness 28 · NOT READY · exit proximity 0
Conviction
26/ 100 · maturity 86%
VScore.3613
Buildup.2129
EMA entry setup.2728
Fundamentals.1647
Volume profile
POC
0.92
Price vs POC
+7.0%
Overhead supply
52%
Runway
+2.4%
Value area 0.75–1.21 · 52% of 120d volume overhead · heavy supply
Contributing sources
| Source | Score | Last seen |
|---|---|---|
| event-calendar | 0.629 | Sep 7, 2026 |
Forward returns
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | +2.86% | +2.86% | 4/20d |
| 40d | +2.86% | +2.86% | 4/40d |